Voxilaprevir

Overview

Voxilaprevir (GS-9857) is a noncovalent, reversible inhibitor of HCV NS3/4A protease inhibitor (PI) with pangenotypic antiviral activity. Voxilaprevir inhibits genotype 1b and 3a wild-type NS3 proteases with K i values of 0.038 nM and 0.066 nM, respectively. Voxilaprevir is an orally active direct-acting antiviral agent ( DAA ) and can be used for HCV infection research.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Hepatitis Virus Infection | Products > Disease Areas > Viral Infection | Products > Disease Areas > Hepatitis C Virus Infection | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > HCV Protease

Product Information

• Catalog No.: HY-19840
• CAS No.: 1535212-07-7
• Molecular Formula: C40H52F4N6O9S
• Molecular Weight: 868.93
• Purity: 99.70%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (2.88 mM); Clear solution
• Availability: In-stock

Source

Original product source